Free Survivorship Teleconferences
Join The Leukemia & Lymphoma Society for the latest information on survivorship related issues during their free teleconferences. Upcoming events include:
Childhood Cancer Survivorship: Challenges, Strategies, Resources
This program will feature Daniel Armstrong, PhD, Professor & Associate Chair, Department of Pediatrics, Director, Mailman Center for Child Development, Director, University of Miami, Sickle Cell Center, University of Miami, Miller School of Medicine, Associate Chief of Staff, Holtz Children's Hospital, University of Miami, Jackson Memorial Medical Center, Miami, FL and Nancy F. Cincotta, MSW, LCSW, ACSW, Psychosocial Director, Camp Sunshine, Casco, ME.
Participants will have the opportunity to ask the presenters questions during the program.
This program is supported by The Leukemia & Lymphoma Society and will be held on 5/26/09 from 12-1:30pm ET. To register for the teleconference, call
(866) 992-9950 ext. 301
You can also access archived teleconferences such as this one: Childhood Leukemia and Lymphoma: An Update on Current and Emerging Therapies
This program featured Sima Jeha, M.D., Director, Leukemia/Lymphoma Developmental Therapeutics, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
